1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Livzon Pharmaceutical Group, Inc. Class A

Livzon Pharmaceutical Group, Inc. Class A

2.44
EUR
+0.06
(+2.52%)
0.27EPS
11.10P/E
3.65BMarket Cap
Oct 23Next Earn
Livzon Pharmaceutical Group, Inc. Class A
FRA:LP6
(Frankfurt Stock Exchange)

Recent

price

2.44

P/E

ratio

11.10

div

yld

8.03%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
2.04
2.38
2.94
3.46
4.14
4.96
5.55
5.83
6
6.33
7.1
8.16
8.53
8.45
8.12
8.53
10.82
Revenue per Share
0.31
0.27
0.33
0.37
0.39
0.47
0.57
3.02
0.73
0.88
1.16
1.2
1.29
1.33
1.42
1.44
1.82
Basic EPS, GAAP
0.22
0.27
-0.13
-0.36
0.04
0.34
0.66
0.7
0.54
0.92
1.02
0.4
1.24
1.65
1.65
1.82
- -
Free Cash Flow per Basic Share
0.04
0.03
0.14
0.14
0.15
0.06
0.17
0.15
0.76
0.59
0.74
0.85
0.88
1.08
0.92
0.73
1.52
Dividend per Share
2.5
2.82
2.99
3.32
2.77
3.15
4.4
7.28
7.2
7.55
8.1
8.77
9.38
9.61
9.62
9.89
9.52
Book Value per Share
2.23
2.55
2.68
3
2.5
2.88
4.12
7.02
6.91
7.23
7.71
8.13
8.75
9.03
9.1
9.21
8.12
Tangible Book Value per Share
1,340
1,331
1,339
1,335
1,338
1,336
1,379
1,464
1,476
1,483
1,482
1,478
1,481
1,472
1,455
1,410
1,016
Basic Weighted Avg Shares
2,727
3,163
3,944
4,619
5,544
6,621
7,652
8,531
8,861
9,385
10,520
12,064
12,630
12,430
11,812
12,020
10,995
Sales/Revenue/Turnover
18.98
14.41
13.35
13.37
11.89
12.33
12.92
14.2
12.47
16.89
22
18.13
17.69
19.56
23.96
23.09
22.84
Operating Margin (%)
121
141
152
169
247
311
362
359
364
385
394
445
652
840
575
574
- -
Depreciation Expense
418
359
442
488
516
623
784
4,429
1,082
1,303
1,715
1,776
1,909
1,954
2,061
2,023
1,846
Net Income, GAAP
15.21
16.27
15.19
16.69
15.09
18.36
17.43
21.61
16.59
15.4
14.39
13.07
16.09
20.36
17.88
15.76
16.08
Effective Tax Rate (%)
15.34
11.36
11.2
10.56
9.31
9.4
10.25
51.91
12.21
13.88
16.3
14.72
15.12
15.72
17.45
16.83
16.79
Profit Margin (%)
1,231
1,387
598
651
497
423
2,660
6,949
7,102
7,580
8,544
7,748
9,591
9,179
8,795
8,898
4,651
Working Capital
67
1
1
550
467
1
1
1
1
- -
370
642
1,986
1,622
1,479
767
44
LT Debt
2,639
3,012
3,180
3,605
4,082
4,810
7,106
11,234
11,750
12,275
13,640
14,311
14,936
14,767
14,906
15,547
14,598
Total Equity
15.56
11.32
12.42
11.66
10.37
10.86
11.35
45.48
8.29
10.74
14.47
11.98
10.99
10.15
12.24
13.14
11.79
Return on Invested Capital (%)
14.25
11.19
12.11
10.97
10.47
11.77
12.11
47.67
8.14
8.56
9.04
10.27
10.94
11.16
10
8.98
8.5
Return on Capital (%)
17.92
13.41
15.1
15.35
14.66
15.48
14.46
51.26
10.1
11.94
14.74
14.14
14.21
14
14.77
14.58
13.41
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2,293
2,790
3,412
LT Borrowings
749
158
26
LT Finance Leases
17
18
18
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,404
1,404
1,404
Market Capitalization
36,248
35,161
28,304

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
16,118
15,661
13,113
Cash, Cash Equivalents & STI
10,650
9,594
7,824
Accounts Receivable, Net
2,248
2,198
1,973
Inventories
1,561
1,528
1,798
Total Current Liabilities
7,220
7,988
8,462
Payables & Accruals
- -
- -
- -
ST Debt
2,293
2,790
3,412
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.94%
2.68%
4.3%
Free Cash Flow
36.16%
37.31%
6.73%
Net Income, GAAP
48.41%
3.41%
-1.84%
Sales/Revenue/Turnover
6.35%
2.91%
1.76%
Total Cash Common Dividend
59.44%
0.27%
-22.93%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,243
3,040
2,799
2,731
11,812
2025
3,181
3,091
- -
2,904
12,020
2026
2,871
2,129
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.41
0.61
0.55
0.43
1.42
2025
0.45
0.73
- -
0.3
1.44
2026
0.41
0.4
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.4
1.01
0.02
0.92
2025
0.01
0.75
- -
0.01
0.73
2026
0.01
0.96
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Livzon Pharmaceutical Group Inc. is an integrated pharmaceutical company engaged in the research, development, manufacturing, and commercialization of a diverse portfolio of healthcare products within the People's Republic of China and globally. The company offers a wide range of finished drug preparations targeting various therapeutic areas, including gastrointestinal health with treatments for conditions like duodenal ulcers and reflux esophagitis, as well as reproductive endocrinology with specialized injections for anovulation. Its product pipeline also addresses neurological disorders, such as a recently approved schizophrenia drug and preparations for nerve growth factor, alongside antiviral medications for respiratory tract infections and a traditional Chinese medicine injection used for fatigue and weakness in cancer patients. Beyond finished pharmaceuticals, Livzon produces active pharmaceutical ingredients (APIs) and intermediates, encompassing areas such as fermented antibiotics, cephalosporins, and compounds for managing hyperlipidemia, diabetes, and cardiovascular conditions. A significant part of its business involves diagnostic reagents and equipment, provided by its subsidiary, Livzon Diagnostics. These in-vitro diagnostic kits are crucial for detecting infectious diseases like HIV and hepatitis, respiratory infections including COVID-19 antibodies, tumor markers, and monitoring drug concentrations, holding substantial market share in China for certain tests. The company is strategically expanding its focus into high-value biologics, developing innovative monoclonal antibodies, biosimilars, and vaccines, with numerous projects in clinical development for oncology and autoimmune diseases. Recent activities include a successful Phase 3 trial for its LZM012 antibody in psoriasis and the acquisition of a controlling stake in Vietnam's Imexpharm, highlighting its international expansion. Founded in 1985 and headquartered in Zhuhai, China, Livzon Pharmaceutical Group Inc. continues to demonstrate steady growth, reporting increased operating income and robust cash flow in its latest quarterly results.